Dose-finding study on meropenem in bacterial pneumonia

Kohei Hara; Shigeru Kono; Hironobu Koga; Kazuo Ishida; Takashige Miyazaki; Akira Sakamoto; Toshiaki Hayashi; Masahiko Yoshimoto; Akira Saito; Ichiro Nakayama; Kazuo Takebe; Takeshi Osonoi; Yasuhisa Kuroda; Masakichi Motomiya; Akira Watanabe; Yoshihiro Honda; Otohiko Kunii; Hajime Nishiya; Jingoro Shimada; Kouya Shiba; Masaki Yoshida; Osamu Sakai; Kihachiro Shimizu; Kyouichi Totsuka; Hiroshi Kino; Hiroyuki Kobayashi; Masahiko Yoshida; Shin Kawai; Hiroaki Takeda; Fumio Matsumoto; Iwao Sakurai; Takeo Imai; Tadashi Tamura; Takayuki Takahashi; Masayuki Morita; Shigeki Odagiri; Kaneo Suzuki; Kou Murohashi; Masaaki Arakawa; Koichi Wada; Takashi Kawashima; Norio Suzuki; Nobuki Aoki; Toshihiko Takeuchi; Yoshimitsu Hayashi; Kazuhide Yamamoto; Toshiyuki Yamamoto; Kanzo Suzuki; Satoru Adachi; Fumio Miki; Nobuhiro Narita; Masayoshi Sawaki; Keiichi Mikasa; Takao Sasaki; Yukio Matsumoto; Yuji Sugimoto; Rinzo Soejima; Masaru Sumi; Toshiharu Matsushima; Masayoshi Kawanishi; Michio Yamakido; Kenji Hasegawa; Keizo Matsumoto; Hirofumi Tanaka; Masaru Nasu; Jun Goto; Atsushi Saito; Hiroshi Fukuhara; Yuei Irabu; Keizo Kikkawa; Yoshiteru Shigeno; Hiroshi Nakamura; Mitsuyoshi Nakashima; Keizo Yamaguchi; Kazuyuki Sugawara

doi:10.11250/chemotherapy1953.40.Supplement1_447

Dose-finding study on meropenem in bacterial pneumonia

Kohei Hara, Shigeru Kono, Hironobu Koga, Kazuo Ishida, Takashige Miyazaki, Akira Sakamoto, Toshiaki Hayashi, Masahiko Yoshimoto, Akira Saito, Ichiro Nakayama, Kazuo Takebe, Takeshi Osonoi, Yasuhisa Kuroda, Masakichi Motomiya, Akira Watanabe, Yoshihiro Honda, Otohiko Kunii, Hajime Nishiya, Jingoro Shimada, Kouya ShibaMasaki Yoshida, Osamu Sakai, Kihachiro Shimizu, Kyouichi Totsuka, Hiroshi Kino, Hiroyuki Kobayashi, Masahiko Yoshida, Shin Kawai, Hiroaki Takeda, Fumio Matsumoto, Iwao Sakurai, Takeo Imai, Tadashi Tamura, Takayuki Takahashi, Masayuki Morita, Shigeki Odagiri, Kaneo Suzuki, Kou Murohashi, Masaaki Arakawa, Koichi Wada, Takashi Kawashima, Norio Suzuki, Nobuki Aoki, Toshihiko Takeuchi, Yoshimitsu Hayashi, Kazuhide Yamamoto, Toshiyuki Yamamoto, Kanzo Suzuki, Satoru Adachi, Fumio Miki, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Takao Sasaki, Yukio Matsumoto, Yuji Sugimoto, Rinzo Soejima, Masaru Sumi, Toshiharu Matsushima, Masayoshi Kawanishi, Michio Yamakido, Kenji Hasegawa, Keizo Matsumoto, Hirofumi Tanaka, Masaru Nasu, Jun Goto, Atsushi Saito, Hiroshi Fukuhara, Yuei Irabu, Keizo Kikkawa, Yoshiteru Shigeno, Hiroshi Nakamura, Mitsuyoshi Nakashima, Keizo Yamaguchi, Kazuyuki Sugawara

研究成果: Article › 査読

抄録

To determine the optimal clinical dose of meropenem (MEPM), a new carbapenem antibiotic for injection, in bacterial pneumonia, a dose-finding study was conducted by the blind method using imipenem/cilastatin (IPM/CS) as the control drug. Patients were given 0.5 g of MEPM a day (L-group) or 1.0 g of MEPM a day (H-group), or 1.0 g/1.0 g of IPM/CS a day (IM-group) for 14 days as a rule. Almost all patients had bacterial pneumonia, but some had pulmonary suppuration, or mycoplasmal pneumonia or primary atypical pneumonia. The results as evaluated by the committee were as follows; 1. In the case of bacterial pneumonia, the clinical efficacy rate was 95.7% (22/23) in the L-group, 79.3% (23/29) in the H-group and 84.0% (21/25) in the IM-group. There was a significant difference between the L-group and the H-group. In the total population, the clinical efficacy rate was 89.3% (25/28) in the L-group, 80.6% (25/31) in the H-group and 79.3% (23/29) in the IM-group. There were no significant differences among the 3 groups. 2. Bacteriologically, the eradication rate was 70% (7/10) in the L-group, 100% (13/13) in the H-group and 75% (6/8) in the IM-group. There were no significant differences among the 3 groups. 3. Side effects were observed in 1 of 35 patients in the H-group and 1 of 32 patients in the IM-group. None were severe, however. 4. The incidence of abnormal changes in laboratory findings was 32.1% (9/28) in the L-group, 32.4% (11/34) in the H-group and 46.4% (13/28) in the IM-group. There were no significant differences among the 3 groups. All the changes were mild in degree. 5. The usefulness rate was 89.3% (25/28) in the L-group, 77.4% (24/31) in the H-group and 73.3% (22/30) in the IM-group. There were no significant differences among the 3 groups. From the above results we concluded that a daily dose of 0.5 g was the optimal clinical dose for MEPM in bacterial pneumonia.

本文言語	English
ページ（範囲）	447-463
ページ数	17
ジャーナル	Chemotherapy
巻	40
DOI	https://doi.org/10.11250/chemotherapy1953.40.Supplement1_447
出版ステータス	Published - 1992 4月
外部発表	はい

ASJC Scopus subject areas

薬理学（医学）
感染症
薬理学
創薬
腫瘍学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.11250/chemotherapy1953.40.Supplement1_447

他のファイルとリンク

引用スタイル

Hara, K., Kono, S., Koga, H., Ishida, K., Miyazaki, T., Sakamoto, A., Hayashi, T., Yoshimoto, M., Saito, A., Nakayama, I., Takebe, K., Osonoi, T., Kuroda, Y., Motomiya, M., Watanabe, A., Honda, Y., Kunii, O., Nishiya, H., Shimada, J., ... Sugawara, K. (1992). Dose-finding study on meropenem in bacterial pneumonia. Chemotherapy, 40, 447-463. https://doi.org/10.11250/chemotherapy1953.40.Supplement1_447

Hara, K, Kono, S, Koga, H, Ishida, K, Miyazaki, T, Sakamoto, A, Hayashi, T, Yoshimoto, M, Saito, A, Nakayama, I, Takebe, K, Osonoi, T, Kuroda, Y, Motomiya, M, Watanabe, A, Honda, Y, Kunii, O, Nishiya, H, Shimada, J, Shiba, K, Yoshida, M, Sakai, O, Shimizu, K, Totsuka, K, Kino, H, Kobayashi, H, Yoshida, M, Kawai, S, Takeda, H, Matsumoto, F, Sakurai, I, Imai, T, Tamura, T, Takahashi, T, Morita, M, Odagiri, S, Suzuki, K, Murohashi, K, Arakawa, M, Wada, K, Kawashima, T, Suzuki, N, Aoki, N, Takeuchi, T, Hayashi, Y, Yamamoto, K, Yamamoto, T, Suzuki, K, Adachi, S, Miki, F, Narita, N, Sawaki, M, Mikasa, K, Sasaki, T, Matsumoto, Y, Sugimoto, Y, Soejima, R, Sumi, M, Matsushima, T, Kawanishi, M, Yamakido, M, Hasegawa, K, Matsumoto, K, Tanaka, H, Nasu, M, Goto, J, Saito, A, Fukuhara, H, Irabu, Y, Kikkawa, K, Shigeno, Y, Nakamura, H, Nakashima, M, Yamaguchi, K & Sugawara, K 1992, 'Dose-finding study on meropenem in bacterial pneumonia', Chemotherapy, vol. 40, pp. 447-463. https://doi.org/10.11250/chemotherapy1953.40.Supplement1_447

@article{52b7fb32e637406aa10b0dc31389535a,

title = "Dose-finding study on meropenem in bacterial pneumonia",

abstract = "To determine the optimal clinical dose of meropenem (MEPM), a new carbapenem antibiotic for injection, in bacterial pneumonia, a dose-finding study was conducted by the blind method using imipenem/cilastatin (IPM/CS) as the control drug. Patients were given 0.5 g of MEPM a day (L-group) or 1.0 g of MEPM a day (H-group), or 1.0 g/1.0 g of IPM/CS a day (IM-group) for 14 days as a rule. Almost all patients had bacterial pneumonia, but some had pulmonary suppuration, or mycoplasmal pneumonia or primary atypical pneumonia. The results as evaluated by the committee were as follows; 1. In the case of bacterial pneumonia, the clinical efficacy rate was 95.7% (22/23) in the L-group, 79.3% (23/29) in the H-group and 84.0% (21/25) in the IM-group. There was a significant difference between the L-group and the H-group. In the total population, the clinical efficacy rate was 89.3% (25/28) in the L-group, 80.6% (25/31) in the H-group and 79.3% (23/29) in the IM-group. There were no significant differences among the 3 groups. 2. Bacteriologically, the eradication rate was 70% (7/10) in the L-group, 100% (13/13) in the H-group and 75% (6/8) in the IM-group. There were no significant differences among the 3 groups. 3. Side effects were observed in 1 of 35 patients in the H-group and 1 of 32 patients in the IM-group. None were severe, however. 4. The incidence of abnormal changes in laboratory findings was 32.1% (9/28) in the L-group, 32.4% (11/34) in the H-group and 46.4% (13/28) in the IM-group. There were no significant differences among the 3 groups. All the changes were mild in degree. 5. The usefulness rate was 89.3% (25/28) in the L-group, 77.4% (24/31) in the H-group and 73.3% (22/30) in the IM-group. There were no significant differences among the 3 groups. From the above results we concluded that a daily dose of 0.5 g was the optimal clinical dose for MEPM in bacterial pneumonia.",

keywords = "Meropenem",

author = "Kohei Hara and Shigeru Kono and Hironobu Koga and Kazuo Ishida and Takashige Miyazaki and Akira Sakamoto and Toshiaki Hayashi and Masahiko Yoshimoto and Akira Saito and Ichiro Nakayama and Kazuo Takebe and Takeshi Osonoi and Yasuhisa Kuroda and Masakichi Motomiya and Akira Watanabe and Yoshihiro Honda and Otohiko Kunii and Hajime Nishiya and Jingoro Shimada and Kouya Shiba and Masaki Yoshida and Osamu Sakai and Kihachiro Shimizu and Kyouichi Totsuka and Hiroshi Kino and Hiroyuki Kobayashi and Masahiko Yoshida and Shin Kawai and Hiroaki Takeda and Fumio Matsumoto and Iwao Sakurai and Takeo Imai and Tadashi Tamura and Takayuki Takahashi and Masayuki Morita and Shigeki Odagiri and Kaneo Suzuki and Kou Murohashi and Masaaki Arakawa and Koichi Wada and Takashi Kawashima and Norio Suzuki and Nobuki Aoki and Toshihiko Takeuchi and Yoshimitsu Hayashi and Kazuhide Yamamoto and Toshiyuki Yamamoto and Kanzo Suzuki and Satoru Adachi and Fumio Miki and Nobuhiro Narita and Masayoshi Sawaki and Keiichi Mikasa and Takao Sasaki and Yukio Matsumoto and Yuji Sugimoto and Rinzo Soejima and Masaru Sumi and Toshiharu Matsushima and Masayoshi Kawanishi and Michio Yamakido and Kenji Hasegawa and Keizo Matsumoto and Hirofumi Tanaka and Masaru Nasu and Jun Goto and Atsushi Saito and Hiroshi Fukuhara and Yuei Irabu and Keizo Kikkawa and Yoshiteru Shigeno and Hiroshi Nakamura and Mitsuyoshi Nakashima and Keizo Yamaguchi and Kazuyuki Sugawara",

year = "1992",

month = apr,

doi = "10.11250/chemotherapy1953.40.Supplement1_447",

language = "English",

volume = "40",

pages = "447--463",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Dose-finding study on meropenem in bacterial pneumonia

AU - Hara, Kohei

AU - Kono, Shigeru

AU - Koga, Hironobu

AU - Ishida, Kazuo

AU - Miyazaki, Takashige

AU - Sakamoto, Akira

AU - Hayashi, Toshiaki

AU - Yoshimoto, Masahiko

AU - Saito, Akira

AU - Nakayama, Ichiro

AU - Takebe, Kazuo

AU - Osonoi, Takeshi

AU - Kuroda, Yasuhisa

AU - Motomiya, Masakichi

AU - Watanabe, Akira

AU - Honda, Yoshihiro

AU - Kunii, Otohiko

AU - Nishiya, Hajime

AU - Shimada, Jingoro

AU - Shiba, Kouya

AU - Yoshida, Masaki

AU - Sakai, Osamu

AU - Shimizu, Kihachiro

AU - Totsuka, Kyouichi

AU - Kino, Hiroshi

AU - Kobayashi, Hiroyuki

AU - Yoshida, Masahiko

AU - Kawai, Shin

AU - Takeda, Hiroaki

AU - Matsumoto, Fumio

AU - Sakurai, Iwao

AU - Imai, Takeo

AU - Tamura, Tadashi

AU - Takahashi, Takayuki

AU - Morita, Masayuki

AU - Odagiri, Shigeki

AU - Suzuki, Kaneo

AU - Murohashi, Kou

AU - Arakawa, Masaaki

AU - Wada, Koichi

AU - Kawashima, Takashi

AU - Suzuki, Norio

AU - Aoki, Nobuki

AU - Takeuchi, Toshihiko

AU - Hayashi, Yoshimitsu

AU - Yamamoto, Kazuhide

AU - Yamamoto, Toshiyuki

AU - Suzuki, Kanzo

AU - Adachi, Satoru

AU - Miki, Fumio

AU - Narita, Nobuhiro

AU - Sawaki, Masayoshi

AU - Mikasa, Keiichi

AU - Sasaki, Takao

AU - Matsumoto, Yukio

AU - Sugimoto, Yuji

AU - Soejima, Rinzo

AU - Sumi, Masaru

AU - Matsushima, Toshiharu

AU - Kawanishi, Masayoshi

AU - Yamakido, Michio

AU - Hasegawa, Kenji

AU - Matsumoto, Keizo

AU - Tanaka, Hirofumi

AU - Nasu, Masaru

AU - Goto, Jun

AU - Saito, Atsushi

AU - Fukuhara, Hiroshi

AU - Irabu, Yuei

AU - Kikkawa, Keizo

AU - Shigeno, Yoshiteru

AU - Nakamura, Hiroshi

AU - Nakashima, Mitsuyoshi

AU - Yamaguchi, Keizo

AU - Sugawara, Kazuyuki

PY - 1992/4

Y1 - 1992/4

N2 - To determine the optimal clinical dose of meropenem (MEPM), a new carbapenem antibiotic for injection, in bacterial pneumonia, a dose-finding study was conducted by the blind method using imipenem/cilastatin (IPM/CS) as the control drug. Patients were given 0.5 g of MEPM a day (L-group) or 1.0 g of MEPM a day (H-group), or 1.0 g/1.0 g of IPM/CS a day (IM-group) for 14 days as a rule. Almost all patients had bacterial pneumonia, but some had pulmonary suppuration, or mycoplasmal pneumonia or primary atypical pneumonia. The results as evaluated by the committee were as follows; 1. In the case of bacterial pneumonia, the clinical efficacy rate was 95.7% (22/23) in the L-group, 79.3% (23/29) in the H-group and 84.0% (21/25) in the IM-group. There was a significant difference between the L-group and the H-group. In the total population, the clinical efficacy rate was 89.3% (25/28) in the L-group, 80.6% (25/31) in the H-group and 79.3% (23/29) in the IM-group. There were no significant differences among the 3 groups. 2. Bacteriologically, the eradication rate was 70% (7/10) in the L-group, 100% (13/13) in the H-group and 75% (6/8) in the IM-group. There were no significant differences among the 3 groups. 3. Side effects were observed in 1 of 35 patients in the H-group and 1 of 32 patients in the IM-group. None were severe, however. 4. The incidence of abnormal changes in laboratory findings was 32.1% (9/28) in the L-group, 32.4% (11/34) in the H-group and 46.4% (13/28) in the IM-group. There were no significant differences among the 3 groups. All the changes were mild in degree. 5. The usefulness rate was 89.3% (25/28) in the L-group, 77.4% (24/31) in the H-group and 73.3% (22/30) in the IM-group. There were no significant differences among the 3 groups. From the above results we concluded that a daily dose of 0.5 g was the optimal clinical dose for MEPM in bacterial pneumonia.

AB - To determine the optimal clinical dose of meropenem (MEPM), a new carbapenem antibiotic for injection, in bacterial pneumonia, a dose-finding study was conducted by the blind method using imipenem/cilastatin (IPM/CS) as the control drug. Patients were given 0.5 g of MEPM a day (L-group) or 1.0 g of MEPM a day (H-group), or 1.0 g/1.0 g of IPM/CS a day (IM-group) for 14 days as a rule. Almost all patients had bacterial pneumonia, but some had pulmonary suppuration, or mycoplasmal pneumonia or primary atypical pneumonia. The results as evaluated by the committee were as follows; 1. In the case of bacterial pneumonia, the clinical efficacy rate was 95.7% (22/23) in the L-group, 79.3% (23/29) in the H-group and 84.0% (21/25) in the IM-group. There was a significant difference between the L-group and the H-group. In the total population, the clinical efficacy rate was 89.3% (25/28) in the L-group, 80.6% (25/31) in the H-group and 79.3% (23/29) in the IM-group. There were no significant differences among the 3 groups. 2. Bacteriologically, the eradication rate was 70% (7/10) in the L-group, 100% (13/13) in the H-group and 75% (6/8) in the IM-group. There were no significant differences among the 3 groups. 3. Side effects were observed in 1 of 35 patients in the H-group and 1 of 32 patients in the IM-group. None were severe, however. 4. The incidence of abnormal changes in laboratory findings was 32.1% (9/28) in the L-group, 32.4% (11/34) in the H-group and 46.4% (13/28) in the IM-group. There were no significant differences among the 3 groups. All the changes were mild in degree. 5. The usefulness rate was 89.3% (25/28) in the L-group, 77.4% (24/31) in the H-group and 73.3% (22/30) in the IM-group. There were no significant differences among the 3 groups. From the above results we concluded that a daily dose of 0.5 g was the optimal clinical dose for MEPM in bacterial pneumonia.

KW - Meropenem

UR - http://www.scopus.com/inward/record.url?scp=0026718548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026718548&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.Supplement1_447

DO - 10.11250/chemotherapy1953.40.Supplement1_447

M3 - Article

AN - SCOPUS:0026718548

SN - 0009-3165

VL - 40

SP - 447

EP - 463

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Dose-finding study on meropenem in bacterial pneumonia

抄録

ASJC Scopus subject areas

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル